Advances in pharmacotherapies that target the cell cycle for treatment of breast cancer: where are we at today?

ABSTRACT Introduction Advances in pharmacotherapies that target cell cycle in breast cancer have transformed the therapeutic armamentarium of breast oncology leading to the approval of CDK4/6 inhibitors plus endocrine therapy as the upfront treatment in the HR+/HER2- metastatic setting. The current challenge is to evaluate the efficacy of these drugs in the early setting. The current challenge is to evaluate the efficacy of these drugs in the early setting. Research is also making progress for other breast cancer subtypes (triple negative and HER 2+ breast cancer). Areas covered The aim of this review is to summarize the recent therapeutic updates regarding the efficacy of CDK4/6 inhibitors in the metastatic and early setting for the treatment of HR+/HER2- breast cancer. The review also presents data regarding the clinical role of CDK4/6 inhibitors in HER2+, triple negative breast cancer, and on therapeutic sequences in resistant tumors. A comprehensive search for the literature was conducted using MEDLINE, ASCO, ESMO, and SABCS databases. Expert Opinion The therapeutic paradigm of breast cancer involving CDK4/6 inhibitors presents some still open discussion points. Further evidence regarding the best treatment strategy in HR+ HER2- metastatic breast cancer and the efficacy of CDK 4/6is in the early stage will be necessary in the next future. Predictive biomarkers of response or resistance need to be validated.

[1]  S. Im,et al.  Abstract GS1-10: Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy , 2023, Cancer Research.

[2]  R. de Sanctis,et al.  Sticking to the Rules: Outcome and Success Rate of Guideline-Based Diarrhea Management in Metastatic Breast Cancer Patients Treated with Abemaciclib , 2023, Journal of clinical medicine.

[3]  P. Neven,et al.  Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. , 2022, The Lancet. Oncology.

[4]  F. Puglisi,et al.  Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review , 2022, ESMO open.

[5]  H. Denys,et al.  LBA18 Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): A randomized, open-label, phase II trial , 2022, Annals of Oncology.

[6]  J. Huober,et al.  LBA15 MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC) , 2022, Annals of Oncology.

[7]  S. Loi,et al.  Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  E. Winer,et al.  Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. , 2022, The New England journal of medicine.

[9]  Anne Jacobson.  Early Switch to Fulvestrant Plus Palbociclib Improves Outcomes in ESR1-Mutated, Estrogen Receptor-Positive Metastatic Breast Cancer , 2022, The oncologist.

[10]  I. Bièche,et al.  Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1 , 2022, BMJ Open.

[11]  M. Berger,et al.  Abstract GS4-08: Comprehensive genomic profiling of patients with breast cancer identifies germline-somatic interactions mediating therapy resistance , 2022, Cancer Research.

[12]  A. Bardia,et al.  AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer , 2022, Therapeutic advances in medical oncology.

[13]  L. Chow,et al.  Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial , 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  R. Greil,et al.  Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03) , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Colleoni,et al.  Systematic review and meta-analysis of post-progression outcomes in ER+/HER2− metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials , 2021, ESMO open.

[16]  Lingli Yao,et al.  Neoadjuvant Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors Combined with Endocrine Therapy in HR+/HER2− Breast Cancer: A Systematic Review and Meta-Analysis , 2021, Oncology Research and Treatment.

[17]  J. Collins,et al.  A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status , 2021, Oncology and Therapy.

[18]  P. Fasching,et al.  Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase 3 randomized MONALEESA-3 trial: updated overall survival. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  Sung-Bae Kim,et al.  Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Ceppi,et al.  CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis , 2021, ESMO open.

[21]  E. Winer,et al.  Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. , 2021, The Lancet. Oncology.

[22]  A. Jager,et al.  Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences , 2020, Drugs.

[23]  N. Lin,et al.  A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer , 2020, Clinical Cancer Research.

[24]  I. Makhoul,et al.  Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial). , 2020 .

[25]  C. Arteaga,et al.  Overcoming Endocrine Resistance in Breast Cancer. , 2020, Cancer cell.

[26]  T. Ishida,et al.  Abstract PD2-04: Different mechanism of CDK4/6 inhibitor resistance between ribociclib and abemaciclib , 2020 .

[27]  M. Goetz,et al.  Abstract PD2-06: Efficacy of abemaciclib based on genomic alterations detected in baseline circulating tumor DNA from the MONARCH 3 study of abemaciclib plus nonsteroidal aromatase inhibitor , 2020 .

[28]  F. Puglisi,et al.  Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity. , 2019, Future oncology.

[29]  K. Goldberg,et al.  CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. , 2019, The Lancet. Oncology.

[30]  A. Prat,et al.  Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. , 2019, The Lancet. Oncology.

[31]  E. Winer,et al.  Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. , 2019 .

[32]  Chiun-Sheng Huang,et al.  Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer , 2019, Clinical Cancer Research.

[33]  U. Dafni,et al.  Breast Cancer Statistics in the European Union: Incidence and Survival across European Countries , 2019, Breast Care.

[34]  P. Neven,et al.  The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 , 2019, JAMA oncology.

[35]  Sarah A. Boswell,et al.  Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity. , 2019, Cell chemical biology.

[36]  S. Chia,et al.  Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database. , 2019, Clinical breast cancer.

[37]  P. Fasching,et al.  NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) early breast cancer (EBC). , 2019, Journal of Clinical Oncology.

[38]  S. Chandarlapaty,et al.  Molecular profiling of ER+ metastatic breast cancers to reveal association of genomic alterations with acquired resistance to CDK4/6 inhibitors. , 2019, Journal of Clinical Oncology.

[39]  S. Chandarlapaty,et al.  Cyclin E mRNA: Assessing Cyclin-Dependent Kinase (CDK) Activation State to Elucidate Breast Cancer Resistance to CDK4/6 Inhibitors. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  S. Loi,et al.  Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  P. Neven,et al.  Abstract PD2-05: Biomarker analysis by baseline circulating tumor DNA alterations in the MONALEESA-3 study , 2019, Poster Discussion Abstracts.

[42]  M. Dowsett,et al.  Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  H. Iwata,et al.  MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer , 2019, npj Breast Cancer.

[44]  K. Gelmon,et al.  Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up , 2019, Breast Cancer Research and Treatment.

[45]  S. Verma,et al.  CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease , 2018, Therapeutic advances in medical oncology.

[46]  A. Vincent-Salomon,et al.  Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  Shuyan Lu,et al.  Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology , 2018, Molecular Cancer Therapeutics.

[48]  Xiaolong Yang,et al.  Targeting the Hippo Pathway for Breast Cancer Therapy , 2018, Cancers.

[49]  S. Loi,et al.  Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer , 2018, The New England journal of medicine.

[50]  S. Loi,et al.  The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. , 2018, Cancer discovery.

[51]  L. Chow,et al.  Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. , 2018, The Lancet. Oncology.

[52]  E. Winer,et al.  Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  P. Fasching,et al.  Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  M. Koehler,et al.  Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer , 2018, Nature Communications.

[55]  D. Slamon,et al.  Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer , 2018, Molecular Cancer Therapeutics.

[56]  G. Hortobagyi,et al.  Abstract PD4-06: First-line ribociclib + letrozole in hormone receptor-positive, HER2-negative advanced breast cancer: Efficacy by baseline circulating tumor DNA alterations in MONALEESA-2 , 2018 .

[57]  S. Loi,et al.  Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer. , 2017, Cancer research.

[58]  M. Goetz,et al.  MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  Shreyas S. Rao,et al.  Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer , 2017, Oncotarget.

[60]  K. Shohdy,et al.  Gastrointestinal adverse effects of cyclin-dependent kinase 4 and 6 inhibitors in breast cancer patients: a systematic review and meta-analysis , 2017, Therapeutic advances in drug safety.

[61]  C. Bakal,et al.  Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer , 2017, Clinical Cancer Research.

[62]  J. Hutcheson,et al.  Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature , 2017, Oncotarget.

[63]  P. Neven,et al.  MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  S. Schnitt,et al.  Retinoblastoma (Rb) protein expression in triple-negative breast cancer. , 2017 .

[65]  C. Hudis,et al.  MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer , 2017, Clinical Cancer Research.

[66]  Zachary L. Skidmore,et al.  NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer , 2017, Clinical Cancer Research.

[67]  K. Gelmon,et al.  Palbociclib and Letrozole in Advanced Breast Cancer. , 2016, The New England journal of medicine.

[68]  E. Winer,et al.  Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. , 2016, The New England journal of medicine.

[69]  Ping Chen,et al.  Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance , 2016, Molecular Cancer Therapeutics.

[70]  A. Bardia,et al.  Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study. , 2016, Breast.

[71]  Tuan S. Nguyen,et al.  Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. , 2016, Cancer discovery.

[72]  M. Dowsett,et al.  Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. , 2016, Cancer research.

[73]  S. Loi,et al.  Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. , 2016, The Lancet. Oncology.

[74]  E. Winer,et al.  Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. , 2016, Cancer cell.

[75]  R. Bernards,et al.  Targeting the RB-E2F pathway in breast cancer , 2016, Oncogene.

[76]  Thomas J. Raub,et al.  Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft , 2015, Drug Metabolism and Disposition.

[77]  R. Pazdur,et al.  FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer , 2015, Clinical Cancer Research.

[78]  C. Boshoff,et al.  Molecular Pathways: Targeting the Cyclin D–CDK4/6 Axis for Cancer Treatment , 2015, Clinical Cancer Research.

[79]  P. Iversen,et al.  Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine , 2014, Investigational New Drugs.

[80]  L. Gelbert,et al.  Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenografts , 2014, Clinical Cancer Research.

[81]  M. O'Connell,et al.  Cell cycle regulation by checkpoints. , 2014, Methods in molecular biology.

[82]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[83]  A. Jukkola-Vuorinen,et al.  The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer , 2013, Breast Cancer Research.

[84]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[85]  Charles M. Perou,et al.  Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. , 2012, Journal of the National Cancer Institute.

[86]  D. Yee,et al.  Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. , 2011, Endocrine-related cancer.

[87]  R. Clarke,et al.  Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. , 2011, Endocrine-related cancer.

[88]  J. Dering,et al.  PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro , 2009, Breast Cancer Research.

[89]  H. Rui,et al.  Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome , 2009, Oncogene.

[90]  E. Knudsen,et al.  RB in Breast Cancer: The Crossroads of Tumorigenesis and Treatment , 2007, Cell cycle.

[91]  P. Vogiatzi.  Cyclin D1 antagonizes BRCA1 repression of estrogen receptor α activity , 2006 .

[92]  Yan Geng,et al.  Requirement for CDK4 kinase function in breast cancer. , 2006, Cancer cell.

[93]  A. Papanikolaou,et al.  Cyclin D1 in breast cancer pathogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  N. Pryer,et al.  Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. , 2004, Molecular cancer therapeutics.

[95]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[96]  A. Pardee.  G1 events and regulation of cell proliferation. , 1989, Science.